Trials Sponsors Conditions Drugs Pricing

Conditions

Covid19 SARS-CoV Infection Thrombocytopenia Vaccination; Complications Venous Thrombosis

Outcome Measures

Primary Outcomes (1)

Functional outcome (modified rankin scale)
through study completion, an average of 1 years

Secondary Outcomes (2)

Recurrent vascular events
through study completion, an average of 1 years
Mortality
through study completion, an average of 1 years

Study Arms (1)

patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination

Other: Retrospective data and biological samples

Interventions

Retrospective data and biological samplesOther

Analysis of data and biological samples collected during hospitalization:

patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

patient hospitalized with atypical thrombosis occurring within 4 weeks of anticovid vaccination

You may qualify if:

atypical thrombosis symptoms onset within 4 weeks of vaccination

You may not qualify if:

Sponsors & Collaborators

University Hospital, Lille
Otherlead

Study Sites (1)

CHU lille

Lille, 59037, France

MeSH Terms

Conditions

COVID-19Severe Acute Respiratory SyndromeVenous ThrombosisThrombocytopenia

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

Charlotte Cordonnier, MD,PhD
University Hospital, Lille
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 27, 2021

First Posted

May 17, 2021

Study Start

April 2, 2021

Actual (reported)

Study Stopped

Collection of the Thrombo-VaxCov Cohort

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

patient hospitalized with atypical thrombosis within 4 weeks of anti-covid vaccination

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations